{
  "id": 5330,
  "text": "BMC Cancer 2016;16:501.Available at: https://www.ncbi.nlm.nih.gov/pubmed/27435245.149.Mileshkin LR, Narayan K, Moore KN, et al.A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174) [abstract].",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: BMC Cancer 2016;16:501.Available at: https://www.ncbi.nlm.nih.gov/pubmed/27435245.149.Mileshkin LR, Narayan K, Moore KN, et al.A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174) [abstract].\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "根据相关临床试验结果，在局部晚期宫颈癌初始治疗中，化疗联合放化疗后追加辅助化疗相比于单纯放化疗在疗效和预后方面并未显示出显著优势。具体而言，辅助化疗的引入尚未证明能够显著提高患者的长期生存率，且可能增加治疗相关的不良反应。因此，在实际临床中，是否选择辅助化疗需综合考虑患者的个体情况以及治疗耐受性，以达到最佳的治疗平衡。\n\n",
  "query": "如果化疗联合放化疗与单纯放化疗相比，作为局部晚期宫颈癌的主要治疗之后的辅助治疗，有何临床试验结果和依据？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 如果化疗联合放化疗与单纯放化疗相比，作为局部晚期宫颈癌的主要治疗之后的辅助治疗，有何临床试验结果和依据？\n\n<reference text>: BMC Cancer 2016;16:501.Available at: https://www.ncbi.nlm.nih.gov/pubmed/27435245.149.Mileshkin LR, Narayan K, Moore KN, et al.A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174) [abstract].\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "根据相关临床试验结果，在局部晚期宫颈癌初始治疗中，化疗联合放化疗后追加辅助化疗相比于单纯放化疗在疗效和预后方面并未显示出显著优势。具体而言，辅助化疗的引入尚未证明能够显著提高患者的长期生存率，且可能增加治疗相关的不良反应。因此，在实际临床中，是否选择辅助化疗需综合考虑患者的个体情况以及治疗耐受性，以达到最佳的治疗平衡。\n\n"
}